Martin Aringer Selected Research

tocilizumab (atlizumab)

7/2023	Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study.
9/2022	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age.
1/2022	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
5/2021	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
3/2021	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis.
1/2020	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
1/2019	Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
1/2018	Tocilizumab in the treatment of giant cell arteritis.
6/2017	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
1/2017	Trial of Tocilizumab in Giant-Cell Arteritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Aringer Research Topics

Disease

27	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2023 - 01/2003
15	Lupus Nephritis 10/2023 - 10/2004
12	Rheumatoid Arthritis 09/2023 - 05/2005
10	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2003
9	Systemic Scleroderma (Systemic Sclerosis) 06/2023 - 08/2005
8	Interstitial Lung Diseases (Interstitial Lung Disease) 06/2023 - 11/2009
8	Giant Cell Arteritis (Horton Disease) 05/2022 - 01/2017
8	Arthritis (Polyarthritis) 01/2019 - 10/2004
7	Infections 01/2024 - 11/2004
7	Rheumatic Diseases (Rheumatism) 01/2022 - 05/2008
5	Connective Tissue Diseases (Connective Tissue Disease) 03/2022 - 12/2007
4	Fatigue 09/2022 - 07/2012
4	Inflammation (Inflammations) 01/2022 - 11/2009
4	Necrosis 01/2020 - 11/2011
4	Proteinuria 01/2020 - 10/2004
3	Pain (Aches) 09/2022 - 01/2003
3	Virus Diseases (Viral Diseases) 01/2022 - 11/2004
3	Mixed Connective Tissue Disease (MCTD) 02/2012 - 08/2005
3	Gout 01/2011 - 04/2008
2	Body Weight (Weight, Body) 10/2023 - 01/2019
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 09/2023 - 06/2023
2	Renal Insufficiency (Renal Failure) 09/2022 - 01/2011
2	Dermatomyositis (Dermatopolymyositis) 01/2022 - 09/2014
2	Delirium 01/2021 - 12/2019
2	Alopecia (Baldness) 12/2020 - 01/2019
2	Bacterial Infections (Bacterial Infection) 01/2020 - 03/2012
2	Fever (Fevers) 12/2019 - 01/2019
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 11/2019 - 11/2016
2	Vasculitis (Vasculitides) 11/2012 - 05/2011
2	Pneumonia (Pneumonitis) 03/2012 - 11/2009
2	Hyperuricemia 08/2009 - 04/2008
2	Nephritis 07/2008 - 10/2004
1	VEXAS syndrome 01/2024
1	Bronchiectasis 09/2023
1	Cutaneous Lupus Erythematosus 01/2023
1	Sleep Initiation and Maintenance Disorders (Insomnia) 09/2022
1	Coronary Disease (Coronary Heart Disease) 09/2022
1	Disease Progression 02/2022
1	Lung Diseases (Lung Disease) 01/2022
1	Panniculitis 01/2022

Drug/Important Bio-Agent (IBA)

14	GlucocorticoidsIBA 09/2023 - 11/2012
13	AutoantibodiesIBA 01/2020 - 01/2003
11	tocilizumab (atlizumab)FDA Link 07/2023 - 11/2011
9	AntibodiesIBA 01/2021 - 08/2005
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2012 - 01/2003
8	Rituximab (Mabthera)FDA Link 12/2022 - 05/2011
8	Infliximab (Remicade)FDA Link 01/2020 - 10/2004
7	nintedanibIBA 09/2023 - 01/2021
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2012
6	Antirheumatic Agents (DMARD)IBA 01/2020 - 11/2011
5	Antinuclear AntibodiesIBA 01/2022 - 02/2012
5	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 10/2004
5	Tumor Necrosis Factor InhibitorsIBA 06/2017 - 01/2003
4	Leflunomide (Arava)FDA LinkGeneric 12/2022 - 06/2017
4	Prednisone (Sone)FDA LinkGeneric 01/2022 - 06/2013
4	Edetic Acid (EDTA)FDA Link 04/2021 - 11/2012
4	CytokinesIBA 07/2012 - 01/2003
3	belimumabIBA 10/2023 - 01/2015
3	Janus Kinase InhibitorsIBA 01/2022 - 06/2017
3	baricitinibIBA 01/2022 - 06/2017
3	Etanercept (Enbrel)FDA Link 01/2020 - 05/2005
3	Phospholipids (Phosphatides)FDA LinkGeneric 12/2019 - 03/2012
3	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 11/2019 - 01/2018
2	Interferon Type IIBA 12/2023 - 01/2023
2	InterferonsIBA 12/2023 - 02/2012
2	voclosporinIBA 10/2023 - 01/2022
2	Tacrolimus (Prograf)FDA LinkGeneric 10/2023 - 01/2020
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2022 - 11/2004
2	anifrolumabIBA 01/2022 - 01/2022
2	Calcineurin InhibitorsIBA 01/2022 - 01/2020
2	Antimalarials (Antimalarial Agents)IBA 11/2021 - 03/2017
2	Antiphospholipid AntibodiesIBA 12/2020 - 01/2019
2	Abatacept (Orencia)FDA Link 01/2020 - 06/2017
2	tofacitinibIBA 01/2020 - 06/2017
2	Adalimumab (Humira)FDA Link 01/2020 - 06/2017
2	sarilumabIBA 01/2020 - 06/2017
2	Biosimilar PharmaceuticalsIBA 01/2020 - 06/2017
2	Certolizumab Pegol FDA Link 01/2020 - 06/2017
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2002
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 06/2017
2	Janus KinasesIBA 01/2020 - 06/2017
2	C-Reactive ProteinIBA 01/2020 - 07/2002
2	golimumab FDA Link 01/2020 - 06/2017
2	AntigensIBA 09/2019 - 05/2008
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 11/2016 - 06/2013
2	EnzymesIBA 01/2015 - 06/2013
2	Azathioprine (Imuran)FDA LinkGeneric 06/2013 - 10/2004
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 11/2012 - 05/2011
2	Uric Acid (Urate)IBA 08/2009 - 04/2008
2	CollagenIBA 08/2005 - 07/2002
1	Leucovorin (Folinic Acid)FDA Link 01/2024
1	Retinaldehyde (Retinal)IBA 10/2023
1	ametantrone (HAQ)IBA 09/2022
1	Ligases (Synthetase)IBA 03/2022

Therapy/Procedure

24	Therapeutics 01/2024 - 01/2003
3	Immunomodulation 03/2022 - 01/2021
2	Plasma Exchange 01/2017 - 11/2004
1	Traction 09/2023
1	Retreatment 12/2022
1	Drug Therapy (Chemotherapy) 02/2022